NCT04028232

Brief Summary

Background: In comparison to general population, persons with Multiple Sclerosis have a higher risk to premature death with an estimate reduced life expectancy from 7 to 14 years. However, risk factors of mortality in MS are not well identified and well known. Following the example of studies carry on cancers survival, socioeconomic status (SES) may have an influence on survival in MS. Objective: The main objective of ECOVIMUS is to estimate net survival according to SES using the European Deprivation Index as a proxy and other major covariates (gender, initial clinical phase and years of disease onset). Methods: In order to answer to our main objective, we will use a retrospective cohort of MS patients with a medical follow-up in one of the 18 centers included in SURVIMUS II, with a MS onset between 1960 and 2015 and with an informed vital at the date of December 31st, 2015. The ecological score of deprivation EDI will be used as a proxy of the socioeconomic status and will be attributed from the geolocalisation to patient's residence address. Net survival is directly associated to the notion of "mortality in excess". This mortality will be estimated comparing the observed mortality in MS patients to mortality in the general population. The advantage of this methodological approach is that cause of death is not needed. Statistical analysis: The influence of socioeconomic status on the excess of mortality will be estimated thanks to a parametric multivariate model of excess rate mortality. This model will be adjusted on other major covariates (gender, age at disease onset, and initial clinical phase) and will include potential complex effects as non-linearity, non-proportionality and interactions. Expected results: We expect to highlight some differences of net survival in MS patients according to socioeconomic group as it was already shown in cancers. This study will complete information on factors of mortality excess in MS and knowledge on socioeconomic inequalities encountered all along MS disease course.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2019

Geographic Reach
1 country

18 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 10, 2019

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

July 19, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 22, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2020

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

January 23, 2020

Status Verified

January 1, 2020

Enrollment Period

10 months

First QC Date

July 19, 2019

Last Update Submit

January 22, 2020

Conditions

Keywords

Multiple SclerosisEpidemiologySocio-Economic StatusNet Survival

Outcome Measures

Primary Outcomes (1)

  • Excess mortality survival

    Net survival is defined as the probability of death in a hypothetical setting where the cause of interest (in our case MS) would be the only possible cause of death. It is directly linked to the concept of the "excess mortality due to the studied disease". Net survival can be calculated according to two settings, either the estimator of survival can be calculated from death due to MS while cause of death are known, either it can be calculated from the excess of mortality due to MS compared to the mortality of the general population obtained from mortality table of the generable population.

    From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.

Secondary Outcomes (2)

  • European Deprivation Index (EDI) proxy of Socio-Economic Status

    From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.

  • Distance to MS expert care center

    From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.

Eligibility Criteria

Age1 Year - 100 Years
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will include all patients registered in 17 selected French OFSEP centres with core dataset with a sufficient level of data (Besançon, Bordeaux, Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Nancy, Nice, Rennes, Saint-Etienne, Strasbourg, Toulouse, Montpellier, Nantes, Nîmes). The minimum required data includes: Diagnosis a of definite or probably MS according to Poser or McDonald criteria. With an MS onset date between January 1st, 1960 and December 31st, 2015. With a postal residence address well informed in the OFSEP database.

You may qualify if:

  • all patients registered in 17 selected French OFSEP centres with core dataset with a sufficient level of data
  • Diagnosis a of definite or probably MS according to Poser or McDonald criteria. With an MS onset date between January 1st, 1960 and December 31st, 2015.
  • With a postal residence address well informed in the OFSEP database.

You may not qualify if:

  • MS patients with less than one year's disease duration by the study end will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

University Hospital Center of CAEN

Caen, Normandy, 14033, France

RECRUITING

University Hospital of Besancon

Besançon, France

RECRUITING

University Hospital of Bordeaux

Bordeaux, France

RECRUITING

University Hospital Centre of Caen

Caen, France

RECRUITING

University Hospital of Clermont Ferrand

Clermont-Ferrand, France

RECRUITING

University Hospital of Dijon

Dijon, France

RECRUITING

University Hospital of Lille

Lille, France

RECRUITING

University Hospital of Lyon

Lyon, France

RECRUITING

University Hospital of Marseille

Marseille, France

RECRUITING

University Hospital of Montpellier

Montpellier, France

RECRUITING

University Hospital of Nancy

Nancy, France

RECRUITING

University Hospital of Nantes

Nantes, France

RECRUITING

University Hospital of Nice

Nice, France

RECRUITING

University hospital Centre of Nîmes

Nîmes, France

RECRUITING

University Hospital of Rennes

Rennes, France

RECRUITING

University Hospital Centre of Saint-Etienne

Saint-Etienne, France

RECRUITING

University Hospital of Strasbourg

Strasbourg, France

RECRUITING

University Hospital Centre of Toulouse

Toulouse, France

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Gilles-Louis DEFER, Professor

CONTACT

Floriane CALOCER, PharmD/PhD Student

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 19, 2019

First Posted

July 22, 2019

Study Start

July 10, 2019

Primary Completion

April 30, 2020

Study Completion

December 31, 2020

Last Updated

January 23, 2020

Record last verified: 2020-01

Locations